Weight management in obesity - Past and present

International Journal of Clinical Practice

Volumn 70, Issue 3, 2016, Pages 206-217

  Haslam, D ^a  

^a Cheyne Society   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DINITROPHENOL; AMFEBUTAMONE PLUS NALTREXONE; AMFEPRAMONE; AMOBARBITAL; AMPHETAMINE DERIVATIVE; ANTIOBESITY AGENT; BELONARIB; BENZPHETAMINE; BIDIETHYLPROPION; CETILISTAT; CHLORPHENTERMINE; DEXAMPHETAMINE; DEXFENFLURAMINE; EMETIC AGENT; FENFLURAMINE; LAXATIVE; LIRAGLUTIDE; LORCASERIN; METHAMPHETAMINE; PENTOBARBITAL; PHENDIMETRAZINE; PHENMETRAZINE; PHENOBARBITAL; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG;

ARTICLE; BODY WEIGHT MANAGEMENT; COMORBIDITY; CULTURAL ANTHROPOLOGY; DIET THERAPY; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG INDUSTRY; DRUG SAFETY; EGYPT; EXERCISE; FOOD; GREECE; HEALTH HAZARD; HISTORY; HUMAN; LIFESTYLE MODIFICATION; LITERATURE; LONG TERM CARE; MIDDLE AGES; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROCESSED FOOD; SEDENTARY LIFESTYLE; URBANIZATION; WEIGHT REDUCTION; BODY WEIGHT; DRUG EFFECTS;

ANTI-OBESITY AGENTS; BODY WEIGHT; HISTORY, 17TH CENTURY; HISTORY, 18TH CENTURY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HISTORY, ANCIENT; HISTORY, MEDIEVAL; HUMANS; OBESITY; WEIGHT LOSS;

EID: 84959484123     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12771     Document Type: Article

References (109)

1. Antl-Weiser W,. The anthropomorphic figurines from Willendorf. Wiss Mitt Niederösterr Landesmuseum 2008; 19: 19-30.
2. Conard NJ,. A female figurine from the basal Aurignacian of Hohle Fels Cave in southwestern Germany. Nature 2009; 459: 248-52.
3. Rich SA,. Midwifery and neolithic Malta: interpreting and contextualizing two terracotta figurines. J Appl Anthropol 2008. http://www.omertaa.org/archive/omertaa0034.pdf (accessed 28 October 2015).
4. Bray GA,. History of obesity. In:, Williams G, Frühbeck G, eds. Obesity: Science to Practice. Oxford, UK: Wiley-Blackwell, 2009: 3-18.
5. Kingshouse. Bible Health. http://www.kingshouse.org/Biblehealth.htm (accessed 28 October 2015).
6. Martin-Rodriguez E, Guillen-Grima F, Martí A, Brugos-Larumbe A,. Comorbidity associated with obesity in a large population: the APNA study. Obes Res Clin Pract 2015; 9: 435-47.
7. Louie SM, Roberts LS, Nomura DK,. Mechanisms linking obesity and cancer. Biochim Biophys Acta 2013; 1831: 1499-508.
8. Dods RF,. Understanding diabetes: a biochemical perspective. ChemMedChem 2013; 8: 1415.
9. Wells JCK,. The Evolutionary Biology of Human Body Fatness: Thrift and Control. Cambridge, UK: Cambridge University Press, 2009.
10. Papavramidou NS, Papavramidis ST, Christopoulou-Aletra H,. Galen on obesity: etiology, effects, and treatment. World J Surg 2004; 28: 631-5.
11. Bloomgarden ZT,. Prevention of obesity and diabetes. Diabetes Care 2003; 26: 3172-8.
12. Shipley O,. A Theory About sin in Relation to Some Facts of Daily Life, Lent Lectures on the 7 Deadly Sins. Oxford: Oxford University Library collection, 1875.
13. Haslam DW, Haslam F,. Fat, Gluttony and Sloth. Obesity in Literature, Art and Medicine. Liverpool, UK: Liverpool University Press, 2009.
14. WHO. Obesity and Overweight. http://www.who.int/mediacentre/factsheets/fs311/en/ (accessed 27 October 2015).
15. Christopoulou-Aletra H, Papavramidou N,. Methods used by the Hippocratic physicians for weight reduction. World J Surg 2004; 28: 513-7.
16. Kryger MH,. Sleep apnea. From the needles of Dionysius to continuous positive airway pressure. Arch Internal Med 1983; 143: 2301-23.
17. Haslam D, Rigby N,. A long look at obesity. Lancet 2010; 376: 85-96.
18. Clapham JC, Arch JR,. Thermogenic and metabolic antiobesity drugs: rationale and opportunities. Diabetes Obes Metab 2007; 3: 259-75.
19. Museum of the Royal Pharmaceutical Society. Developing Treatments: Obesity, 2009. http://www.rpharms.com/museum-pdfs/obesity.pdf (accessed 28 October 2015).
20. Haslam D,. The Weight of Obsession. A Brief but Wide, History, 2015. https://commonreader.wustl.edu/c/the-weight-of-obsession (accessed 28 October 2015).
21. Cutting WC, Mehrtens HG, Tainter ML,. Actions and uses of dinitrophenol: promising metabolic applications. J Am Med Assoc 1933; 101: 193-5.
22. Tainter M, Cutting WC, Stockton AB,. Use of dinitophenol in nutritional disorders: a critical survey of clinical results. Am J Public Health 1934; 24: 1045-53.
23. Heal DJ, Smith SL, Gosden J, Nutt DJ,. Amphetamine, past and present-a pharmacological and clinical perspective. J Psychopharmacol 2013; 27: 479-96.
24. Colman E,. Anorectics on trial: a half century of federal regulation of prescription appetite suppressants. Ann Intern Med 2005; 143: 380-5.
25. Martel A,. Preludin (phenmetrazine) in the treatment of obesity. Can Med Assoc J 1957; 76: 117-20.
26. Cohen S,. Diethylpropion (Tenuate): an infrequently abused anorectic. Psychosomatics 1977; 18: 28-33.
27. le Riche WH, van Belle G,. Study of phendimetrazine bitartrate as an appetite suppressant in relation to dosage, weight loss and side effects. Can Med Assoc J 1962; 87: 29-31.
28. Rasmussen N,. America's first amphetamine epidemic 1929-1971: a quantitative and qualitative retrospective with implications for the present. Am J Public Health 2008; 98: 974-85.
29. Nelson DL, Gehlert DR,. Central nervous system biogenic amine targets for control of appetite and energy expenditure. Endocrine 2006; 29: 49-60.
30. Hendricks EJ, Srisurapanont M, Schmidt SL, et al., Addiction potential of phentermine prescribed during long-term treatment of obesity. Int J Obes 2013; 38: 292-8.
31. Drug Amendments of 1962. Pub L No. 87-781, 76 Stat 780, 1962. http://www.gpo.gov/fdsys/pkg/STATUTE-76/pdf/STATUTE-76-Pg780.pdf (accessed 28 October 2015).
32. United States Food and Drug Administration. The Code of Federal Regulations of the United States of America: 201.200 Disclosures of Drug Efficacy Study Evaluations in Labeling and Advertising. Washington, DC, USA: The Office of the Federal Register National Archives and Records Administration, 1999.
33. Weintraub M,. Long-term weight control study I (weeks 0 to 34). Clin Pharmacol Ther 1992; 51: 586-94.
34. Weintraub M,. Long-term weight control study: conclusions. Clin Pharmacol Ther 1992; 51: 642-6.
35. United States Food and Drug Administration. Guidance for the Clinical Evaluation of Weight-Control Drugs, 1996. http://www.fda.gov/ohrms/dockets/98fr/03d-0570-gdl0001.pdf. Superseded by 2007 guidance. http://www.fda.gov/downloads/Drugs/%e2%80%a6/Guidances/ucm071612.pdf (accessed 28 October 2015).
36. EEC Council Regulations. Council Regulation (EEC) No 2309/93 of 22 July 1993 Laying Down Community Procedures for the Authorization and Supervision of Medicinal Products for Human and Veterinary use and Establishing a European Agency for the Evaluation of Medicinal Products, 1993. http://ec.europa.eu/health/files/eudralex/vol-1/reg-1993-2309/reg-1993-2309-bg.pdf (accessed 28 October 2015).
37. McCann U, Hatzidimitriou G, Ridenour A, et al., Dexfenfluramine and serotonin neurotoxicity: further preclinical evidence that clinical caution is indicated. Pharmacol Exp Ther 1994; 269: 792-8.
38. Kramer MS, Lane DA,. Aminorex, dexfenfluramine, and primary pulmonary hypertension. J Clin Epidemiol 1998; 51: 361-4.
39. Connolly HM, Crary JL, McGoon MD, et al., Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337: 581-8.
40. Morrow DJ,. Fen-Phen Maker to Pay Billions In Settlement of Diet-Injury Cases. The New York Times, October 8, 1999. http://www.nytimes.com/1999/10/08/business/fen-phen-maker-to-pay-billions-in-settlement-of-diet-injury-cases.html (accessed 28 October 2015).
41. Haddock CK, Poston WS, Dill PL, Foreyt JP, Ericsson M,. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord 2002; 26: 262-73.
42. Kim KK, Cho HJ, Kang HC, et al., Effects on weight reduction and safety of short-term phentermine administration in Korean obese people. Yonsei Med J 2006; 47: 614-25.
43. Kang JG, Park CY, Kang JH, Park YW, Park SW,. Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity. Diabetes Obes Metab 2010; 12: 876-82.
44. Saraç F, Pehlivan M, Celebi G, Saygili F, Yilmaz C, Kabalak T,. Effects of sibutramine on thermogenesis in obese patients assessed via immersion calorimetry. Adv Ther 2006; 23: 1016-29.
45. Halford JC, Boyland EJ, Cooper SJ, et al., The effects of sibutramine on the microstructure of eating behaviour and energy expenditure in obese women. J Psychopharmacol 2010; 24: 99-109.
46. Araújo JR, Martel F,. Sibutramine effects on central mechanisms regulating energy homeostasis. Curr Neuropharmacol 2012; 10: 49-52.
47. Rucker D, Padwal R, Li SK, Curioni C, Lau DC,. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007; 335: 1194-9.
48. Beaston P,. BPCA Executive Summary: Clinical Review for New Drug Application 20-632, SE5-021, 2005. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM163209.pdf (accessed 28 October 2015).
49. James WP,. The SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients. Eur Heart J 2005; 7: L44-8.
50. James WP, Caterson ID, Coutinho W, et al., Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010; 363: 905-17.
51. United States Food and Drug Administration. Meridia (Sibutramine): Market Withdrawal Due to Risk of Serious Cardiovascular Events, 2010. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm228830.htm (accessed 28 October 2015).
52. European Medicines Agency. Questions and Answers on the Suspension of Medicines Containing Sibutramine, 2010. http://www.ema.europa.eu/docs/en-GB/document-library/Referrals-document/Sibutramine-107/WC500094238.pdf (accessed 28 October 2015).
53. Caterson ID, Finer N, Coutinho W, et al., Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes Obes Metab 2012; 14: 523-30.
54. An H, Sohn H, Chung S,. Phentermine, Sibutramine and affective disorders. Clin Psychopharmacol Neurosci 2013; 11: 7-12.
55. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L,. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155-61.
56. Douglas IJ, Langham J, Bhaskaran K, Brauer R, Smeeth L,. Orlistat and the risk of acute liver injury: self controlled case series study in UK Clinical Practice Research Datalink. BMJ 2013; 346: f1936.
57. Roche. Xenical Summary of Product Characteristics, 2013. http://www.medicines.org.uk/emc/document.aspx?documentid=1746 (accessed 28 October 2015).
58. Robson PJ,. Therapeutic potential of cannabinoid medicines. Drug Test Anal 2014; 6: 24-30.
59. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A, Rothman RB,. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007; 370: 1706-13.
60. United States Food and Drug Administration. Briefing Document NDA 21-888 Zimulti (Rimonabant) Tablets, 20 mg, 2007. http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4306b1-fda-backgrounder.pdf (accessed 28 October 2015).
61. European Medicines Agency. The European Medicines Agency Recommends Suspension of the Marketing Authorisation of Acomplia, 2009. http://www.ema.europa.eu/ema/index.jsp?curlpages/news-and-events/news/2009/11/news-detail-000244.jsp (accessed 28 October 2015).
62. Drugs.com. Accomplia. http://www.drugs.com/acomplia.html (accessed 28 October 2015).
63. Richard D,. Cognitive and autonomic determinants of energy homeostasis in obesity. Nat Rev Endocrinol 2015; 11: 489-501.
64. United States Food and Drug Administration. Lorcaserin Briefing Information: Endocrinologic and Metabolic Drugs Advisory Committee, 2012. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm225628.htm (accessed 28 October 2015).
65. Smith SR, Weissman NJ, Anderson CM, et al.,; Behavioral modification and lorcaserin for overweight and obesity management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010; 363: 245-56.
66. Weissman NJ, Sanchez M, Koch GG, Smith SR, Shanahan WR, Anderson CM,. Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials. Circ Cardiovasc Imaging 2013; 6: 560-7.
67. United States Food and Drug Administration. FDA Approves Belviq to Treat Some Overweight or Obese Adults, 2012. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm309993.htm (accessed 28 October 2015).
68. Fidler MC, Sanchez M, Raether B, et al.,; BLOSSOM Clinical Trial Group. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 2011; 96: 3067-77.
69. Arena Pharmaceuticals. Lorcaserin for Obesity Passes Major Safety Milestone. Month-12 Independent Echocardiographic Data Safety Monitoring Board Review Strengthens Lorcaserin's Emerging Cardiovascular Safety Profile, 2008. http://invest.arenapharm.com/common/mobile/iphone/releasedetail.cfm?ReleaseID&320197%26CompanyID=ARNA (accessed 28 October 2015).
70. European Medicines Agency. Withdrawal of the Marketing Authorisation Application for Belviq (Lorcaserin), 2013. http://www.ema.europa.eu/docs/en-GB/document-library/Medicine-QA/2013/05/WC500143811.pdf (accessed 28 October 2015).
71. Scozzafava A, Supuran CT, Carta F,. Antiobesity carbonic anhydrase inhibitors: a literature and patent review. Expert Opin Ther Pat 2013; 23: 725-35.
72. Unites States Food and Drug Administration. FDA Approves Weight-Management Drug Qsymia, 2012. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312468.htm (accessed 28 October 2015).
73. Aronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S, Gadde KM,. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. Obesity (Silver Spring) 2013; 21: 2163-71.
74. Gadde KM, Allison DB, Ryan DH, et al., Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomized, placebo-controlled, phase 3 trial. Lancet 2011; 377: 1341-52.
75. Allison DB, Gadde KM, Garvey WT, et al., Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 2012; 20: 330-42.
76. Garvey WT, Ryan DH, Look M, et al., Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012; 95: 297-308.
77. Colman E, Golden J, Roberts M, Egan A, Weaver J, Rosebraugh C,. The FDA's assessment of two drugs for chronic weight management. N Engl J Med 2012; 367: 1577-9.
78. European Medicines Agency. Refusal of the Marketing Authorisation for Qsiva (Phentermine/Topiramate), 2012. http://www.ema.europa.eu/docs/en-GB/document-library/Summary-of-opinion-Initial-authorisation/human/002350/WC500134085.pdf (assessed 28 October 2015).
79. ™ CardiovascuLAr MorbIdity and Mortality (AQCLAIM) Study in Subjects With Documented Cardiovascular Disease. http://www.clinicaltrialsregister.eu/ctr-search/search?queryAQCLAIM (accessed 28 October 2015).
80. Unites States Food and Drug Administration. Contrave (Naltrexone 4 mg, 8 mg/Bupropion HCL 90 mg Extended Release Tablet) Briefing Document, NDA 200063, 2010. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm235671.pdf (accessed 28 October 2015).
81. United States Food and Drug Administration. Center for Drug Evaluation and Research. Application Number 200063Orig1s000. Summary Review, 2014. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2014/200063Orig1s000SumR.pdf (accessed 28 October 2015).
82. Wadden TA, Foreyt JP, Foster GD, et al., Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity 2011; 19: 110-20.
83. Guettier J-MP,. Contrave NDA Approval Letter, 2014. http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2014/200063Orig1s000ltr.pdf (accessed 28 October 2015).
84. Cleveland Clinic. Clinical Trial Testing Safety of Obesity Drug Contrave Halted; 50 Percent Interim Data Released by the Study's Executive Committee. http://my.clevelandclinic.org/about-cleveland-clinic/newsroom/releases-videos-newsletters/2015-5-12-clinical-trial-testing-safety-of-obesity-drug-contrave-halted (accessed 28 October 2015).
85. European Medicines Agency. Mysimba Summary of Product Characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/003687/WC500185580.pdf (accessed 28 October 2015).
86. European Medicines Agency. Victoza Summary of Product Characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/001026/WC500050017.pdf (accessed 28 October 2015).
87. Marre M, Shaw J, Brandle M, et al., Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26: 268-78.
88. Nauck M, Frid A, Hermansen K, et al., Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009; 32: 84-90.
89. Garber A, Henry R, Ratner R, et al., Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473-81.
90. Zinman B, Gerich J, Buse JB, et al., Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009; 32: 1224-30.
91. Russell-Jones D, Vaag A, Schmitz O, et al., Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009; 52: 2046-55.
92. Buse JB, Rosenstock J, Sesti G, et al., Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39-47.
93. Pratley RE, Nauck M, Bailey T, et al., Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010; 375: 1447-56.
94. ® (Liraglutide Injection). http://www.accessdata.fda.gov/drugsatfda-docs/label/2015/022341s023lbl.pdf (accessed 28 October 2015).
95. Turton MD, O'Shea D, Gunn I, et al., A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996; 379: 69-72.
96. van Can J, Sloth B, Jensen CB, et al., Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond) 2014; 38: 784-93.
97. Pi-Sunyer X, Astrup A, Fujioka K, et al., A randomized, controlled trial of 3.0 mg liraglutide in weight management. N Engl J Med 2015; 373: 11-22.
98. Smith JP,. Saxenda NDA Approval Letter, 2014. http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2014/206321Orig1s000ltr.pdf (accessed 28 October 2015).
99. European Medicines Agency. Saxenda Summary of Product Characteristics, 2015. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/003780/WC500185786.pdf (accessed 28 October 2015).
100. United States Food and Drug Administration. FDA Approves Weight-Management Drug Saxenda, 2014. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427913.htm (accessed 28 October 2015).
101. European Medicines Agency. Assessment Report: Saxenda, 2015. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/003780/WC500185788.pdf (accessed 28 October 2015).
102. Yamada Y, Kato T, Ogino H, Ashina S, Kato K,. Cetilistat (ATL-962), a novel pancreatic lipase inhibitor, ameliorates body weight gain and improves lipid profiles in rats. Horm Metab Res 2008; 40: 539-43.
103. Kopelman P, Bryson A, Hickling R, et al., Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obes (Lond) 2007; 31: 494-9.
104. Kopelman P, Groot Gde H, Rissanen A, et al., Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical). Obesity (Silver Spring) 2010; 18: 108-15.
105. ® Tablets 120 mg in Japan for the Treatment of Obesity With Complications, 2013. http://www.takeda.com/news/2013/20130920-5991.html (accessed 28 October 2015).
106. Gadde KM, Yonish GM, Foust MS, Wagner HR,. Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. J Clin Psychiatr 2007; 68: 1226-9.
107. ™ Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients, 2015. http://ir.orexigen.com/phoenix.zhtml?c&207034%26p=irol-newsArticle%26ID=1336796 (accessed 28 October 2015).
108. Kim DD, Krishnarajah J, Lillioja S, et al., Efficacy and safety of beloranib for weight loss in obese adults: a randomized controlled trial. Diabetes Obes Metab 2015; 17: 566-72.
109. An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes Mellitus. https://clinicaltrials.gov/ct2/show/NCT02324491 (accessed 28 October 2015).